Moxsh Overseas Educon Limited is an Indian-listed education services provider specializing in a high-margin, dual-service ecosystem that integrates **overseas career counseling** with **proprietary ed-tech medical coaching**. Established in **2018**, the company has transitioned from a traditional consultancy into a technology-driven platform, addressing the critical supply-demand gap in the Indian medical education sector. --- ### **The Medical Education Ecosystem: Core Business Segments** The company operates a unified **Coaching and Counseling** segment, strategically designed to capture revenue at multiple stages of a medical student’s career path. * **MOKSH Academy (Ed-Tech & Test Prep):** * Provides online coaching via a proprietary **Android and iOS App** for global medical licensing exams, including **USMLE (USA)**, **PLAB (UK)**, and **FMGE/NExT (India)**. * **NExT (National Exit Test):** A mandatory licensing requirement for all Indian medical graduates, creating a captive market. * **Performance:** Maintains a **100% pass rate** for **USMLE** students. The academy currently contributes **50% of total company revenues**. * **Mobility & Counseling (MOKSH Brand):** * Facilitates placement for students in international medical universities. * **Expansion:** Diversifying beyond **MBBS** into Engineering, Humanities, and Management in **Germany, France, and Italy**. * **MBBS in India Counseling Support:** * A digital service for **NEET UG** aspirants, providing online guidance for the **12 lakh** students who qualify for seats annually. * **Ticket Size:** Average service fee of **₹15,000** per student. * **Healthcare (Meduclinic Healthcare Pvt Ltd):** * A wholly-owned subsidiary launching "Edu-Clinics"—hybrid digital classrooms and primary healthcare clinics operated by doctors. --- ### **Market Dynamics and Competitive Positioning** Moxsh distinguishes itself through a "Combo" service model, significantly increasing the **Average Revenue Per Student (ARPU)** compared to traditional agents. | Metric | Moxsh Overseas | Industry Average | | :--- | :--- | :--- | | **Average Revenue Per Student** | **₹325,000+** | **₹150,000** | | **FMGE Pass Rate** | **High Success Focus** | **18% (2025 Avg)** | | **Product Pricing** | **Premium (2x US competitors)** | **Standard** | **Addressable Market Opportunities:** * **USMLE (USA):** Estimated at **₹1,000 Crores** due to the scarcity of Indian PG seats (**24,000** government seats for **110,000** graduates). * **FMGE / NExT:** Estimated at **₹500 Crores** driven by a historical **80% failure rate** in licensing exams. * **EU Mobility:** Estimated at **₹500 Crores** as Indian private medical education costs (**>₹75 Lakhs**) now exceed European public university costs. --- ### **Strategic Pivot: Global Talent Mobility & B2B Expansion** To mitigate the **50% decline** in traditional MBBS markets (Russia, Ukraine, China), the company is re-engineering its model toward the **European Union (EU)** and **B2B technology**. * **Skilled Workforce Migration (Germany):** * **Ausbildung (VET):** Targeting **25,000** student placements in **2025-26** with a projected **10X growth** over five years. * **Healthcare:** Addressing Germany’s demand for **20,000 nurses** annually (Market size: **₹500 Crore**). * **XERA B2B Platform:** A proprietary aggregator for unorganized education agents across **India, Dubai, Qatar, Sri Lanka, and Germany**. * **Institutional Integration:** Exclusive contracts with **Kokshetau State University (Kazakhstan)** and **University of Georgia (Tbilisi)** to embed **MOKSH Academy** coaching into their formal medical curriculums. * **Strategic Alliances:** Partnership with **Safalta.com (Amar Ujala Group)** to distribute MBBS products to a lead base of **25,000** students. --- ### **Financial Performance and Capital Structure** The company returned to profitability in **FY 2024-25** following a downturn in the previous fiscal year. **Standalone Financial Summary (₹ in Lakhs):** | Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Income** | **989.68** | **1,107.96** | **1,230.97** | | **Profit After Tax (PAT)** | **1.57** | **(225.40)** | **100.60** | **Capital Restructuring & Fund Raising:** * **Bonus Issue:** Completed a **3:1 bonus issue** in **October 2024**, increasing paid-up capital from **₹2.24 Crore** to **₹8.96 Crore**. * **Preferential Allotment (Jan 2026):** Issued **3,77,600** shares and **1,60,000** warrants at **₹80** per unit (a premium over the **90-day VWAP** of **₹63.84**), raising approximately **₹4.30 Crore**. * **Promoter Holding:** **62.43%** as of March 31, 2025. --- ### **Operational Infrastructure: The "Studium" Model** The company is transitioning from a purely digital model to a hybrid physical presence. * **Centralized Sales:** All operations are managed via the **All India Counseling Center** in **Bhopal**, generating **25,000 to 50,000** inquiries annually through digital marketing. * **Physical Footprint:** Currently operates **5** company-owned centers and **14** franchisee (**FOCO**) agreements. * **Capital Deployment:** **₹121.50 Lakhs** in capital advances are being capitalized for the construction of "Studiums" (hybrid classrooms/clinics) starting in **FY 2025**. --- ### **Risk Factors and Mitigation** Investors should note specific financial and regulatory challenges: * **Audit Qualifications:** As of **November 2025**, auditors issued a **Qualified Conclusion** regarding **₹3.33 Crore - ₹3.59 Crore** in trade receivables overdue for over **2 years**. Management maintains these are fully recoverable and has not provided for impairment. * **Regulatory Volatility:** The **2024 NEET UG scam** caused a **70-day delay** in student decision-making, impacting seasonal revenue cycles. * **Geopolitical Sensitivity:** Business remains sensitive to stability in **Russia, Georgia, and Kazakhstan**. The company is mitigating this by shifting focus to **Italy, Germany, and Spain**. * **Unappraised Estimates:** Fund deployment schedules are based on **internal management estimates** and have not been appraised by external agencies or banks.